[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.155.6. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
December 1990

Amelioration of Cholinergic-Induced Pancreatitis With a Selective Cholecystokinin Receptor Antagonist

Author Affiliations

From the the Department of Surgery, Yale University School of Medicine, New Haven, Conn (Drs Bilchik and Modlin); the Department of Surgery, University of Maryland School of Medicine, Baltimore, and Baltimore Veterans Affairs Hospital (Dr Zucker); and the Department of Surgery, Creighton University, Omaha, Neb (Dr Adrian).

Arch Surg. 1990;125(12):1546-1549. doi:10.1001/archsurg.1990.01410240024004
Abstract

• Acute edematous pancreatitis follows excessive cholinergic stimulation in patients exposed to anticholinesterase-containing insecticides. We describe the role of cholecystokinin and the benefits of cholecystokinin receptor blockade in this form of pancreatitis. A cholinergic mimetic (carbachol) was administered to rats weighing 300 to 350 g and produced a form of edematous pancreatitis that mimics that seen in humans. Animals received carbachol intraperitoneally, either alone (250 μg/kg of body weight) or with cholecystokinin-receptor antagonist devazepide (3 mg/kg of body weight) and were killed 4 hours later. Carbachol administration resulted in a 19% increase in pancreatic weight, a fourfold increase in serum amylase levels, and a 14-fold increase in serum lipase levels. Plasma cholecystokinin levels, however, were not altered. Devazepide administered prior to cholinergic hyperstimulation blocked pancreatic weight increase and reduced elevations in serum amylase levels twofold and lipase levels fourfold. Although cholecystokinin levels are not elevated in this model of pancreatitis, blockade of even low, background concentrations of this regulatory peptide is beneficial.

(Arch Surg. 1990;125:1546-1549)

References
1.
Adler G, Kern HF, Scheele GA.  Experimental models and concepts in acute pancreatitis . In: Go VLW, ed. The Exocrine Pancreas: Biology, Pathobiology and Diseases . New York, NY: Raven Press; 1986:317-341.
2.
Wener J, Simon MA, Hoff HE.  Production of acute pancreatitis in dogs by the administration of mecholyl . Gastroenterology . 1950;15:125-130.
3.
Lampel M, Kern HF.  Acute interstitial pancreatitis in the rat induced by excessive doses of a pancreatic secretagogue . Virchows Arch A . 1977;373:97-117.Article
4.
Mouret J.  Contribution à l'étude des cellules glandulaires (pancreas) . J Anat Physiol . 1895;31:221-236.
5.
Niederau C, Liddle RA, Ferrell LA, Grendell JA.  Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice . J Clin Invest . 1986;78:1056-1063.Article
6.
Hosotani R, Chowdhury P, McKay D, Rayford PL.  Effect of L364718, a new CCK antagonist, on amylase secretion in isolated rat pancreatic acini . Pancreas . 1988;3:95-98.Article
7.
Cseka M, Brown B, Birath K.  Range of alpha-amylase activities in human serum and urine and correlations with some other alpha-amylase methods . Clin Chim Acta . 1969;26:445-453.Article
8.
Vogel WC, Zieve L.  A rapid and sensitive turbidimetric method for serum lipase based upon the differences between the lipase of normal and pancreatitis serum . Clin Chem . 1963;27:168-178.
9.
Bacarese-Hamilton AJ, Adrian TE, Bloom SR.  Measurement and characterization of human cholecystokinin-like immunoreactivity (CCK-LI) in tissue by radioimmunoassay . Clin Chim Acta . 1984;144:213-224.Article
10.
Bacarese-Hamilton AJ, Adrian TE, Chohan P, Bloom SR.  Rat immunoreactive cholecystokinin (CCK): characterization using two chromatographic techniques . Regul Pept . 1985;11:149-158.Article
11.
Adrian TE, Bacarese-Hamilton AJ, Bloom SR.  Measurement of cholecystokinin octapeptide using a new specific radioimmunoassay . Peptides . 1985;6:11-16.Article
12.
Dressel TD, Goodale RL, Arneson MA, Borner JW.  Pancreatitis as a complication of anticholinesterase insecticide intoxication . Ann Surg . 1978;189:199-204.Article
13.
Bartholomew C.  Acute scorpian pancreatitis in Trinidad . BMJ . 1970;1:666-668.Article
14.
Gardner JD, Jensen RT.  Regulation of pancreatic enzyme secretion in vitro . In: Johnson LR, ed. Physiology of the Gastrointestinal Tract . New York, NY: Raven Press; 1981:831-871.
15.
Niederau C, Ferell LD, Grendell JH.  Onset, course, and regression of caerulein -induced necrotizing pancreatitis in mice . Dig Dis Sci . 1984:29:962.
16.
Zucker KA, Adrian TE, Modlin IM.  Cholecystokinin receptor antagonist blocks caerulein -induced pancreatitis . Surg Forum . 1987;38:142-144.
17.
Modlin IM, Bilchik AJ, Zucker KA, Adrian TE, Sussman J, Graham SM.  Cholecystokinin augmentation of 'surgical' pancreatitis: benefits of receptor blockade . Arch Surg . 1989;124:574-578.Article
18.
Steer ML, Meldolesi J.  Cell biology of experimental pancreatitis . N Engl J Med . 1987;316:144-150.Article
19.
Powers RE, Saluja AK, Houlihan MJ, Steer ML.  Diminished agonist-stimulated inositol triphosphate generation blocks stimulus-secretion coupling in mouse pancreatic acini during diet-induced experimental pancreatitis . J Clin Invest . 1986;77:1668-1674.Article
20.
Konturek SJ, Tasler J, Obtulowicz W.  Effect of atropine on pancreatic responses to endogenous and exogenous cholecystokinin . Am J Dig Dis . 1972;17:911-917.Article
21.
You CH, Chey WY.  Atropine abolishes the potentiation effect of secretin and cholecystokinin-octapeptide on exocrine secretion in humans . Pancreas . 1988;3:99-103.Article
×